Older Age and Larger Prostate Volume Are Associated with Stress Urinary Incontinence after Plasmakinetic Enucleation of the Prostate

Table 2

Baseline characteristics and perioperative data of the two groups.

Variable	Patients without SUI; (); Mean ± SD (range) or median (range) or number patients (%)	Patients with SUI; (); Mean ± SD (range) or median (range) or no patients (%)	value
Baseline characteristic
Age (yr)			<0.001
<70	727 (60.2%)	10 (12.5%)
≥70	481 (39.8%)	70 (87.5%)
BMI (kg/m^2)			0.853
<24	632 (52.3%)	41 (51.3%)
≥24	576 (47.7%)	39 (48.8%)
Diabetes	184 (15.0%)	16 (20.0%)	0.254
Hypertension	520 (43.0%)	32 (40%)	0.594
No. preop treatment (%)
Blockers	560 (43.0%)	32 (40.0%)	0.269
5-Reductase inhibitor	616 (50.9%)	43 (53.8%)	0.633
Both	424 (35.1%)	29(36.3%)	0.835
Bladder stone	158 (13.1%)	9 (11.3%)	0.637
Prostate volume (ml)			<0.001
<90	948 (78.5%)	14 (17.5%)
≥90	260 (21.5%)	66 (82.5%)
International Prostate Symptom Score
Voiding symptoms	15 (5–20)	13 (7–20)	0.847
Storage symptoms	14 (1–15)	13 (2–15)	0.055
Total score	23 (12–35)	19 (16–35)	0.078
Quality of life score	5.2 ± 0.8 (2–6)	5.0 ± 1.2 (2–6)	0.037
Max flow rate (ml/s)	6.7 ± 3.2 (0–15)	6.7 ± 4.3 (0–18)	0.947
Postvoid residual urine (ml)	124.2 ± 261.3 (0–2000)	164.9 ± 276.0 (0–1000)	0.179
Serum total PSA (ng/ml)	5.6 ± 6.8 (0.6–39.2)	8.3 ± 7.4 (1.0–22.3)	0.002
Learning period			0.122
<50 cases	45	5
≥50 cases	1,164	74
Operation time (min)	76.7 ± 44.2 (20–230)	93.9 ± 47.7 (30–240)	0.001
Enucleation time (min)	18.6 ± 7.6 (11–60)	17.9 ± 6.3 (10–35)	0.437
Resected weight (g)	42.2 ± 16.0 (19.9–154.5)	45.5 ± 16.4 (17.9–84.2)	0.069
Hospital stay (days)	4.9 ± 2.1 (3–9)	4.6 ± 2.0 (3–10)	0.195
Catheter time (days)	2.1 ± 1.5 (1–7)	2.0 ± 1.4 (1–6)	0.468

BMI: body mass index, PSA: prostate specific antigen, No. preop treatment: number with each specific preoperative treatment.